These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 32447795)

  • 61. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Opioid Use Disorder Treatment and Potential Interactions With Novel COVID-19 Medications: A Clinical Perspective.
    Mansuri Z; Shah B; Trivedi C; Beg U; Patel H; Jolly T
    Prim Care Companion CNS Disord; 2020 Jul; 22(4):. PubMed ID: 32628368
    [No Abstract]   [Full Text] [Related]  

  • 63. Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders.
    Scholzen E; Zeng AM; Schroeder KM
    Adv Anesth; 2019 Dec; 37():65-86. PubMed ID: 31677660
    [No Abstract]   [Full Text] [Related]  

  • 64. Medication-assisted treatment for opioid use disorder.
    Kaplan L
    Nurse Pract; 2019 Mar; 44(3):10-12. PubMed ID: 30585906
    [No Abstract]   [Full Text] [Related]  

  • 65. Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges.
    Zweben JE; Sorensen JL; Shingle M; Blazes CK
    J Addict Med; 2021 Nov-Dec 01; 15(6):454-460. PubMed ID: 33323695
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 67. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Just call it "treatment".
    Friedmann PD; Schwartz RP
    Addict Sci Clin Pract; 2012 Jun; 7(1):10. PubMed ID: 23186149
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
    Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
    J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
    [TBL] [Abstract][Full Text] [Related]  

  • 70. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 71. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Global opioid agonist treatment: a review of clinical practices by country.
    Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
    Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
    [TBL] [Abstract][Full Text] [Related]  

  • 75. School Nurses: Living the Framework During COVID-19.
    Combe LG
    NASN Sch Nurse; 2020 Jul; 35(4):183-187. PubMed ID: 32452274
    [No Abstract]   [Full Text] [Related]  

  • 76. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In brief: Over-the-counter Narcan nasal spray.
    Med Lett Drugs Ther; 2023 May; 65(1675):72. PubMed ID: 37155252
    [No Abstract]   [Full Text] [Related]  

  • 78. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.
    Crist RC; Doyle GA; Nelson EC; Degenhardt L; Martin NG; Montgomery GW; Saxon AJ; Ling W; Berrettini WH
    Pharmacogenomics J; 2018 Jan; 18(1):173-179. PubMed ID: 27958381
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.